Please cite this article in press as : Assaraf , Y . G . , et al . , The folate receptor as a rational therapeutic target for personalized cancer treatment . Drug Resist . Updat . ( 2014 ) , http : / / dx . doi . org / 10 . 1016 / j . drup . 2014 . 10 . 002 ARTICLE IN PRESS G Model YDRUP - 538 ; No . of Pages 7 Drug Resistance Updates xxx ( 2014 ) xxx – xxx Contents lists available at ScienceDirect Drug Resistance Updates jo ur nal homepage : www . elsevier . com / locate / drup Review The folate receptor as a rational therapeutic target for personalized cancer treatment Yehuda G . Assaraf a , ∗ , Christopher P . Leamon b , Joseph A . Reddy b a The Fred Wyszkowski Cancer Research Laboratory , Faculty of Biology , Technion - Israel Institute of Technology , Haifa , Israel b Endocyte , Inc . , West Lafayette , IN , USA a r t i c l e i n f o Article history : Received 11 June 2014 Received in revised form 29 August 2014 Accepted 5 October 2014 Keywords : Folate Folate receptor Endocytosis Cancer Targeted therapeutics Small molecule drug conjugates Personalized medicine a b s t r a c t Conventional cancer treatment modalities have several limitations including lack of sufﬁcient efﬁcacy , serious untoward toxicity , as well as innate and acquired drug resistance . In contrast , targeted imaging agents can identify patients with receptors overexpressed on the surface of cancer cells , thus allow - ing appropriate selection of patients for personalized treatment with a desirable targeted therapeutic . The folate receptor ( FR ) has been identiﬁed as a new molecularly targeted entity , which is highly over - expressed on the surface of a spectrum of solid tumor cells , including ovarian , kidney , lung , brain , endometrial , colorectal , pancreatic , gastric , prostate , testicular , bladder , head and neck , breast , and non - small cell lung cancer . Folic acid conjugation is a novel approach for targeting FR - expressing tissues for personalized treatment . With the development of FR (cid:2) - targeted therapies comes a concomitant pre - requisite for reliable methods for the quantiﬁcation of FR (cid:2) tissue expression . Therefore , attaching a radioactive probe to folic acid to target diseased tissue has become a novel and powerful imaging tech - nique . Currently available diagnostic tools frequently require invasive surgical biopsy . In contrast , the noninvasive single - photon emission computed tomography - based companion imaging agent , 99m Tc - etarfolatide ( 99m Tc - EC20 ) , is in development for use as a companion diagnostic with the FR (cid:2) - targeted folate conjugate , vintafolide ( EC145 ) , to identify patients whose tumors express FR (cid:2) . Vintafolide is a folic acid conjugate of Vinca alkaloid ( desacetylvinblastine hydrazide ) that targets FR (cid:2) - expressing tumors , thereby disrupting microtubule polymerization . 99m Tc - etarfolatide is taken up by FR - positive tumors and allows for noninvasive , whole - body monitoring of FR (cid:2) expression status throughout treatment . The combination of vintafolide plus etarfolatide has been evaluated in three Phase 2 studies for the treatment of various solid tumors , including ovarian , endometrial , peritoneal , and platinum - resistant ovarian can - cer , as well as lung cancer . Patients with FR - positive tumors , as identiﬁed by etarfolatide uptake , have had better clinical outcomes than patients with FR - negative tumors , indicating the potential of etarfo - latide as a companion biomarker for predicting vintafolide response . Targeted therapies combined with a reliable companion diagnostic test represent a novel approach toward efﬁcient personalized medicine for malignant and nonmalignant disorders . Furthermore , the recent availability of the crystal structures of FR (cid:2) and FR (cid:3) in complex with folates and antifolates forms a realistic basis for the rational design and implementation of novel FR - targeted drugs for the treatment of cancer and inﬂammatory disorders . © 2014 Published by Elsevier Ltd . Contents 1 . Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00 2 . Role of the folate receptor in folate metabolism and cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00 3 . Folate - based personalized medicine : the importance of a reliable quantiﬁcation test for the folate receptor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00 4 . Current clinical status of agents targeting the folate receptor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00 ∗ Corresponding author at : The Fred Wyszkowski Cancer Research Laboratory , Faculty of Biology , Technion - Israel Institute of Technology , Haifa 32000 , Israel . Tel . : + 972 4 8294211 ; fax : + 972 4 8225153 . E - mail address : assaraf @ tx . technion . ac . il ( Y . G . Assaraf ) . http : / / dx . doi . org / 10 . 1016 / j . drup . 2014 . 10 . 002 1368 - 7646 / © 2014 Published by Elsevier Ltd . Please cite this article in press as : Assaraf , Y . G . , et al . , The folate receptor as a rational therapeutic target for personalized cancer treatment . Drug Resist . Updat . ( 2014 ) , http : / / dx . doi . org / 10 . 1016 / j . drup . 2014 . 10 . 002 ARTICLE IN PRESS G Model YDRUP - 538 ; No . of Pages 7 2 Y . G . Assaraf et al . / Drug Resistance Updates xxx ( 2014 ) xxx – xxx 4 . 1 . Farletuzumab . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00 4 . 2 . Vintafolide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00 4 . 3 . IMGN853 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00 5 . Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00 Competing interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00 Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00 1 . Introduction Conventional chemotherapeutic agents target and eradicate rapidly dividing cells ( Vanneman and Dranoff , 2012 ) . However , they are limited by signiﬁcant untoward toxicities to healthy tis - sues , frequently emerging inherent and acquired drug resistance in various solid tumors , and a narrow therapeutic index ( Gonen and Assaraf , 2012 ; Livney and Assaraf , 2013 ; Straussman et al . , 2012 ; Vanneman and Dranoff , 2012 ) . In pioneering studies published in 1986 , it was ﬁrst shown that targeted recombinant antibodies to the Her2 / neu oncogene product can speciﬁcally block the prolifer - ation of tumor cells overexpressing neu in nude mice ( Drebin et al . , 1986 ) . Over the years , conventional cancer treatment has been greatly improved by the addition of an increasing number of new molecularly targeted agents , which inhibit molecular pathways crucial for tumor growth , maintenance , and metastasis ( Vanneman and Dranoff , 2012 ) . Such targeted and personalized cancer treat - ment uses the detailed molecular characteristics of a tumor and its microenvironment to allow tailored therapies to improve treat - ment outcomes , reduce toxicity to healthy tissues , and overcome drug resistance , thereby improving the beneﬁt / risk proﬁle ( Gonen and Assaraf , 2012 ; Livney and Assaraf , 2013 ) . However , lack of sufﬁcient efﬁcacy , reported side effects , and multidrug resistance phenomena often reduce the potential clinical impact of such ther - apies ( Banerjee and Kaye , 2013 ; Sia et al . , 2013 ; Straussman et al . , 2012 ) . Another challenge associated with targeted therapies involves determining which genetic aberrations are driving disease and whether or not they are potential therapeutic targets ( Awada and Aftimos , 2013 ; Burrell et al . , 2013 ; Gerlinger et al . , 2014 ; Mendelsohn , 2013 ) . Moreover , mutated genes in cancer cells may be able to bypass the canonical molecular pathway or may contain irrelevant genetic alterations , both of which would allow them to evade the activity of targeted therapeutic treatments ( Mendelsohn , 2013 ; Straussman et al . , 2012 ) . Hence , biomarkers can be readily used for patient stratiﬁcation , thereby selecting patients who are likely to respond to a targeted therapy ; however , such predictive biomarkers are generally lacking and are urgently needed ( Awada and Aftimos , 2013 ; Banerjee and Kaye , 2013 ; Baumann et al . , 2012 ; Jonsson and Bergh , 2012 ; Mendelsohn , 2013 ) . Careful selection of the best imaging modality to identify suitable biomarkers is also necessary ( Awada and Aftimos , 2013 ) . The discovery and develop - ment of molecularly targeted drugs have led to the emergence of companion diagnostics for patient selection ( Gonzalez de Castro et al . , 2013 ) . Along with them comes the critical need to ensure their robust clinical validation , in which the detection of speciﬁc biomarkers can be linked to patient outcomes ( Gonzalez de Castro et al . , 2013 ) . As a result of these challenges , the search for rational therapeutic targets for cancer treatment is ongoing . 2 . Role of the folate receptor in folate metabolism and cancer Folates occur in an oxidized form as folic acid , or in physiolog - ically and biosynthetically active reduced tetrahydrofolate forms ( Gonen and Assaraf , 2012 ; Ifergan and Assaraf , 2008 ) . Reduced folates are absolutely essential for the synthesis of DNA and RNA , amino acid metabolism , and methylation reactions ; therefore , reduced folates are needed for cell growth , proliferation , and sur - vival ( Gonen and Assaraf , 2012 ) . Dietary folates are absorbed in the upper small intestine ( Zhao and Goldman , 2013 ) , metabolized in the liver to 5 - methyltetrahydrofolate , the major circulating form of folate ( Gonen and Assaraf , 2012 ; Ifergan and Assaraf , 2008 ) , and subsequently circulated through the bloodstream and delivered to the various tissues and organs . Cellular uptake of folates proceeds through three main routes ( Gonen and Assaraf , 2012 ; Ifergan and Assaraf , 2008 ) . In the ﬁrst route , uptake occurs via the proton - coupled folate transporter ( PCFT / SLC46A1 ) , which is responsible for intestinal folate absorp - tion at the acidic pH of the upper small intestine ( Ifergan and Assaraf , 2008 ; Qiu et al . , 2006 ; Zhao and Goldman , 2013 ) . The key role of PCFT in obligatory intestinal folate absorption has been established in studies with hereditary folate malabsorption ( HFM ) , a congenital disorder in which loss - of - function mutations in PCFT result in low folate levels in the blood and cerebrospinal ﬂuid ( Lasry et al . , 2008 ; Qiu et al . , 2006 ; Zhao et al . , 2007 ) . HFM manifests within the ﬁrst few months after birth with anemia , recurrent or chronic diarrhea , hypogammaglobulinemia , severe infection , and failure to thrive ( Lasry et al . , 2008 ; Qiu et al . , 2006 ; Zhao et al . , 2007 ) . The second route involves the ubiquitously expressed reduced folate carrier ( RFC / SLC19A1 ) , which is the primary pathway for reduced folate uptake into various tissues under physiological pH ( Gonen and Assaraf , 2012 ; Ifergan and Assaraf , 2008 ) . Unlike PCFT , which is a proton - driven folate co - transporter , RFC functions as an anion exchanger capable of recognizing reduced folates ( but with very low afﬁnity for folic acid ) and organic phosphates ( Matherly et al . , 2014 ; Zhao and Goldman , 2013 ) . Finally , as folates cannot directly penetrate the cell membrane because of their hydrophilic anionic nature , cellular uptake also occurs via endocytosis through folate receptors ( FRs ) ( Gonen and Assaraf , 2012 ; Ifergan and Assaraf , 2008 ; Zhao et al . , 2007 ; Elnakat and Ratnam , 2006 ) . FRs are glycosylphosphatidylinositol - anchored proteins that bind folic acid and 5 - methyltetrahydrofolate with high afﬁnity ( K d : 10 − 9 – 10 − 10 M ) ( Elnakat and Ratnam , 2006 ; Ifergan and Assaraf , 2008 ; Parker et al . , 2005 ) . Of the four known isoforms ( (cid:2) , (cid:3) , (cid:4) , and (cid:5) ) , FR (cid:2) and FR (cid:3) are anchored to the plasma membrane and bind folic acid with the highest afﬁnity ( Elnakat and Ratnam , 2006 ; Gonen and Assaraf , 2012 ; Ifergan and Assaraf , 2008 ; Parker et al . , 2005 ) . Cells that express FR (cid:2) are more efﬁcient in folate uptake because FR (cid:2) binds folic acid with a binding afﬁnity of 0 . 34 nM and 5 - methyltetrahydrofolate with a binding afﬁnity of 1 nM ( K d ∼ 10 − 9 – 10 − 10 M ) ( Della - Longa and Arcovito , 2013 ) . In nor - mal tissues and organs , FR (cid:2) expression is restricted to only a few sites , which include kidney , lung , choroid plexus , and placenta , where FR (cid:2) is conﬁned to the luminal surface of polarized epithelia and , therefore , is not in contact with circulating folates or intra - venously administered folic acid conjugates ( Elnakat and Ratnam , 2006 ; Gonen and Assaraf , 2012 ; Muller , 2012 ; Parker et al . , 2005 ; Weitman et al . , 1992 ) . FR (cid:3) expression is restricted mainly to the placenta and white blood cells of myeloid lineage , including acti - vated macrophages ( Elnakat and Ratnam , 2006 ; Gonen and Assaraf , 2012 ; Jager et al . , 2012 ) . Numerous studies have shown that FR (cid:2) is markedly overex - pressed on the surface of various tumor types , including ovarian , Please cite this article in press as : Assaraf , Y . G . , et al . , The folate receptor as a rational therapeutic target for personalized cancer treatment . Drug Resist . Updat . ( 2014 ) , http : / / dx . doi . org / 10 . 1016 / j . drup . 2014 . 10 . 002 ARTICLE IN PRESS G Model YDRUP - 538 ; No . of Pages 7 Y . G . Assaraf et al . / Drug Resistance Updates xxx ( 2014 ) xxx – xxx 3 82 81 74 64 56 56 19 18 16 13 13 11 8 4 0 10 20 30 40 50 60 70 80 90 100 Ovaria n NSCLC Kidney Endometria l Colorecta l Breast Pancreas Brai n Gastric Live r Prostat e Testicula r Bladder Head and Neck % C ases F R P o s i t i ve Fig . 1 . Folate receptor expression among a wide variety of human tumors ( unpublished immunohistochemical data , Endocyte Inc . ) . FR , folate receptor ; NSCLC , non - small cell lung cancer . kidney , lung , brain , endometrial , colorectal , pancreatic , gastric , prostate , testicular , bladder , head and neck , and breast cancers , as well as non - small cell lung cancer ( NSCLC ; Fig . 1 ) ( Christoph et al . , 2013 ; Crane et al . , 2012 ; Elnakat and Ratnam , 2006 ; Nunez et al . , 2012 ; Parker et al . , 2005 ; Ross et al . , 1994 ; Toffoli et al . , 1997 ; Weitman et al . , 1992 ) , with increased expression levels com - pared with cognate normal tissue ( Parker et al . , 2005 ; Ross et al . , 1994 ; Weitman et al . , 1992 ) . Evidence also suggests that FR expres - sion increases with advancing disease stage ( Kalli et al . , 2008 ; Siu et al . , 2012 ; Toffoli et al . , 1997 ) and that overexpression of FR (cid:2) is a negative prognostic factor for breast , colorectal , ovarian , and endometrial cancer ( Chen et al . , 2012 ; Hartmann et al . , 2007 ; Shia et al . , 2008 ; Teng et al . , 2012 ) . Thus , FR is viewed as a therapeutic target that may provide an effective option for targeted person - alized cancer therapy . Recently , Wibowo et al . ( 2013 ) described six distinct crystallographic models of human FR (cid:2) and FR (cid:3) that provide key insights into the biological trafﬁcking of FR and delin - eate distinct binding modes of folates and antifolates to these FRs . Moreover , this study described the 3 - D structure of these human FRs in complex with three clinically important antifolate anti - cancer drugs including pemetrexed ( Alimta ® ) , aminopterin , and methotrexate . Hence , these novel structural ﬁndings set the stage for the rapid design and implementation of unique , FR - targeted , folate - conjugated drugs for the treatment of cancer and inﬂamma - tory diseases . 3 . Folate - based personalized medicine : the importance of a reliable quantiﬁcation test for the folate receptor Development of FR (cid:2) - targeted therapies has led to the need for reliable methods of detecting and quantifying FR (cid:2) expression , par - ticularly in cases where frequency and degree of expression are variable . Such quantitative assays may be useful prognostic mark - ers and predictors of response to treatment ( Toffoli et al . , 1998 ) . Patients who express high levels of FR (cid:2) should logically have the best response to FR - targeted therapies . Thus , sensitive , speciﬁc , reliable , and robust quantitative methods of FR (cid:2) expression are greatly needed . Immunohistochemistry of formalin - ﬁxed , parafﬁn - embedded tissue is commonly used for quantiﬁcation of FR (cid:2) levels ( Despierre et al . , 2013 ) , but issues with reproducibility of immunohistochemistry assays have been noted previously across laboratories and instrument platforms ( Wolff et al . , 2007 ) , as have issues with the potential detection of nonfunctional and functional receptors ( Parker et al . , 2005 ; Siu et al . , 2012 ) . Furthermore , detec - tion of FR (cid:2) levels by immunohistochemistry in metastatic lesions requires surgical removal or biopsy ( Siu et al . , 2012 ) , which often is not possible for practical and ethical reasons . Other approaches include radioligand binding assays , quantitative polymerase chain reaction , ﬂow cytometry , electrochemiluminescent assays , and ﬂuorescence in situ hybridization , each of which has its own limita - tions , including the need for tumor biopsy sampling ( Bremer et al . , 2013 ; Bueno et al . , 2001 ; Chen et al . , 2012 ; Christoph et al . , 2013 ; Crane et al . , 2012 ; Despierre et al . , 2013 ; Fisher et al . , 2008 ; Franklin et al . , 1994 ; Garin - Chesa et al . , 1993 ; Li et al . , 1996 ; Nunez et al . , 2012 ; O’Shannessy et al . , 2011 , 2013 ; Parker et al . , 2005 ; Ross et al . , 1994 ; Siu et al . , 2012 ; Toffoli et al . , 1997 , 1998 ; Veggian et al . , 1989 ; Weitman et al . , 1992 ) . Noninvasive imaging is another approach that can be used to select patients with FR - expressing tumors , as FR (cid:2) is expressed on the surface of tumor cells ( Salazar and Ratnam , 2007 ; Sega and Low , 2008 ) . Folate - targeted imaging agents have included 67 Ga ( 67 Ga - DF - Folate ) , which , although FR - speciﬁc , leads to intesti - nal accumulation , making abdominal tumor imaging challenging ( Sega and Low , 2008 ) . Another agent , 111 In - DPTA - folate , has exhibited tumor uptake with good contrast , but its use was suspended because of high costs of 111 In , as well as its rel - atively long radiochemical half - life ( 2 . 8 days ) ( Sega and Low , 2008 ) . 99m Tc , which involves single - photon emission computed tomography ( SPECT ) - based imaging , has a short half - life ( 6 h ) , low cost , and low emitted energy , making it the radioisotope of choice for folate - targeted applications ( Sega and Low , 2008 ) . Etarfolatide ( EC20 ) , one such 99m Tc - based imaging agent , binds FR - expressing tumors very speciﬁcally ( Leamon et al . , 2002 ; Reddy et al . , 2004 ) . Etarfolatide is currently being co - developed as a com - panion imaging agent along with the FR (cid:2) - targeted therapeutic agent , vintafolide ( EC145 ) ( Morris et al . , 2014 ; Pribble and Edelman , 2012 ; Reddy et al . , 2007 ) . This imaging test enables whole - body , real - time detection of “folate receptor status” throughout the course of vintafolide treatment without the need for inva - sive tissue biopsies ( Morris et al . , 2014 ; Pribble and Edelman , 2012 ) . Etarfolatide consists of 99m Tc complexed to a short folate - linked peptide derivative of folic acid ( Fig . 2 ) ( Leamon et al . , 2002 ; Pribble and Edelman , 2012 ) . 99m Tc - etarfolatide shows rapid pharmacokinetic distribution from the bloodstream and binds to FR - positive tumors and normal kidneys , where it is eliminated via the urine mostly in a nonmetabolized form ( Leamon et al . , Please cite this article in press as : Assaraf , Y . G . , et al . , The folate receptor as a rational therapeutic target for personalized cancer treatment . Drug Resist . Updat . ( 2014 ) , http : / / dx . doi . org / 10 . 1016 / j . drup . 2014 . 10 . 002 ARTICLE IN PRESS G Model YDRUP - 538 ; No . of Pages 7 4 Y . G . Assaraf et al . / Drug Resistance Updates xxx ( 2014 ) xxx – xxx H 2 N HN Tc N N O N N S CO 2 H CO 2 H CO 2 H O O O O O N NH 2 HN HN HN Targeting ligand ( Folate ) Covalent bond Imaging agent ( 99m Tc ) Fig . 2 . Chemical structure of 99m Tc - etarfolatide . 2002 ; Pribble and Edelman , 2012 ) . In comparison with other SPECT agents , etarfolatide has higher binding afﬁnity , better tumor uptake , and improved clearance through the kidneys , making it the most promising FR - targeted imaging agent ( Sega and Low , 2008 ) . 99m Tc - etarfolatide was ﬁrst evaluated in 154 patients with a variety of solid tumors , including 119 patients harboring renal cell carcinoma , and it was found to be well tolerated ( Fisher et al . , 2008 ) . SPECT images of etarfolatide uptake were correlated with immunohistochemical analysis of FRs in 123 patients with available tissue . In all , 68 % of patients had tumors with increased 99m Tc - etarfolatide uptake , and consistently , 67 % of patients had FR (cid:2) expression as determined by immunohistochemistry . Agreement between methods was 61 % overall , with 72 % agreement of posi - tive results and 38 % agreement of negative results . The discrepancy was thought to be caused by immunohistochemistry performed mainly on unmatched primary tumor tissue that had been collected several years before the scan , whereas scans had assessed mainly metastatic lesions ( Fisher et al . , 2008 ) . 4 . Current clinical status of agents targeting the folate receptor 4 . 1 . Farletuzumab Several FR - targeted agents are currently in development . Far - letuzumab ( MORAb - 003 ) is a humanized FR (cid:2) - targeted monoclonal antibody derived from the murine antibody , LK26 ( Konner et al . , 2010 ; Teng et al . , 2012 ) . In preclinical studies , farletuzumab elicited robust antibody - dependent cellular cytotoxicity and complement - dependent cytotoxicity , thus inhibiting the growth of human ovarian tumor xenografts ( Teng et al . , 2012 ) . In addition , it report - edly blocked tumor growth through inhibition of FR (cid:2) - mediated Lyn kinase phosphorylation ( Konner et al . , 2010 ) . In a Phase 2 study in women with ﬁrst - relapse , platinum - sensitive ovar - ian , fallopian tube , and primary peritoneal cancers , farletuzumab given in combination with carboplatin / taxane , followed by single - agent farletuzumab maintenance , was associated with substantial clinical activity , improved duration of response , and extended duration of second remission , equaling or exceeding initial remis - sion ( Armstrong et al . , 2013 ) . It was concluded from this study that farletuzumab with carboplatin and taxane may enhance the response rate and duration of response in patients with platinum - sensitive ovarian cancer with ﬁrst relapse after remission duration of 6 – 18 months . Based on these encouraging ﬁndings , a Phase 3 study was undertaken in patients with platinum - sensitive recur - rent ovarian cancer ( Walters et al . , 2013 ) . These patients were given paclitaxel , carboplatin , and farletuzumab , but the trial failed to meet its primary endpoint of progression - free survival ( PFS ) . The post hoc exploratory analysis from this study demonstrated a trend toward improved PFS in some patient subsets , and further analysis is ongoing ( Walters et al . , 2013 ) . Another Phase 3 study in patients with platinum - resistant ovarian cancer who received paclitaxel with farletuzumab or paclitaxel with placebo was termi - nated early because the study did not meet pre - speciﬁed criteria for continuation ( Walters et al . , 2013 ) . Farletuzumab is currently being investigated in a Phase 2 , placebo - controlled study for use in patients with FR (cid:2) - expressing metastatic adenocarcinoma of the lung ( NCT01218516 ) ( Thomas et al . , 2013 ) . 4 . 2 . Vintafolide Vintafolide is a water - soluble conjugate of folic acid and the Vinca alkaloid , desacetylvinblastine hydrazide ( DAVLBH ) ( Fig . 3 ) ( Pribble and Edelman , 2012 ) . DAVLBH exerts its pharmacologic activity by disrupting microtubule polymerization via binding to (cid:3) - tubulin . As a result , it prevents cell division through inhibi - tion of mitotic spindle formation , inducing apoptosis in mitotically active cells ( Pribble and Edelman , 2012 ) . Folic acid and DAVLBH are conjugated through a hydrophilic peptide spacer and a self - immolative disulﬁde linker system to form vintafolide ( Dosio et al . , 2010 ; Pribble and Edelman , 2012 ) . The disulﬁde linker allows the release of DAVLBH inside cancer cells following receptor - mediated endocytosis and reduction within the endosomal milieu ( Fig . 4 ) ( Pribble and Edelman , 2012 ) . Vintafolide binds with high afﬁnity to FRs present on the sur - face of various cancer cells . Together with its companion imaging agent , etarfolatide , vintafolide has been evaluated in three Phase 2 studies in patients with advanced epithelial ovarian , primary per - itoneal , or endometrial cancer ( study EC - FV - 02 ; NCT00507741 ) ; in patients with progressive lung adenocarcinoma ( study EC - FV - 03 ; NCT00511485 ) ; and in patients with platinum - resistant ovarian Vintafolide Etarfolatide • Folic acid conjugated to DAVLBH ( desacetylvinblastine hydrazide ) a potent Vinca alkaloid derivative • MW = 1917 • Relative affinity to Folate Receptor : 0 . 46 ( folic acid 1 . 0 ) • Rapidly cleared from circulation ( t 1 / 2 = 26 min . ) • Dose 2 . 5 mg • Folic acid conjugated to peptidic metal - chelating moiety ; labeled with 99m Tc • MW = 746 • Relative affinity to Folate Receptor : 0 . 92 ( folic acid 1 . 0 ) • Rapidly cleared from circulation ( t 1 / 2 = 25 min . ) • Dose : 0 . 1 mg Fig . 3 . Properties of vintafolide and etarfolatide . Please cite this article in press as : Assaraf , Y . G . , et al . , The folate receptor as a rational therapeutic target for personalized cancer treatment . Drug Resist . Updat . ( 2014 ) , http : / / dx . doi . org / 10 . 1016 / j . drup . 2014 . 10 . 002 ARTICLE IN PRESS G Model YDRUP - 538 ; No . of Pages 7 Y . G . Assaraf et al . / Drug Resistance Updates xxx ( 2014 ) xxx – xxx 5 The reduced folate carrier present on all cells binds folates with a low affinity ( Kd = 10 - 5 M ) and is used by most antifolates . Folate conjugates will not enter cell through the reduced folate carrier . Upon binding to the folate receptor ( Kd = 10 - 10 M ) , the conjugate is internalized via endocytosis 2 Folate conjugate binds the folate receptor 1 Folate receptor recycles back to cell surface 5 The drug is cleaved inside endosome 3 Drug escapes endosome and exerts activity on cell 4 Fig . 4 . Mechanism of action of vintafolide . cancer ( study EC - FV - 04 ; NCT00722592 ; the PRECEDENT study ) ( Edelman et al . , 2012a ; Konner et al . , 2010 ; Morris et al . , 2014 ; Naumann et al . , 2013 ) . In each of these clinical studies , patients were categorized as FR + + ( 100 % ; all lesions positive ) , FR + ( 10 % – 90 % ; at least 1 lesion positive , but not all positive ) , or FR − ( 0 % ; no lesions positive ) ( Edelman et al . , 2012b ; Morris et al . , 2014 ; Naumann et al . , 2013 ) . Results from these studies show that FR + tumors with 99m Tc - etarfolatide uptake had better outcomes than FR - negative tumors , indicating that etarfolatide is a promising companion biomarker predictive of response to vintafolide . In the open - label Phase 2 EC - FV - 02 vintafolide study in patients with advanced epithelial ovarian , primary peritoneal , or endome - trial cancer , median overall survival ( OS ) was 14 . 6 months in patients with FR + + tumors , 11 . 6 months in patients with FR + tumors , and 2 . 7 months in patients with FR − tumors ( Morris et al . , 2014 ) . The disease control rate ( DCR ) was highest in patients with FR + + tumors ( 57 % ) compared with FR + patients ( 43 % ) and FR − patients ( 25 % ) ( Morris et al . , 2014 ) . Irrespective of FR expression status , the DCR was 40 % ( Morris et al . , 2014 ) . The most common grade 3 vintafolide drug - related toxicities were constipation ( 8 % ) and fatigue ( 8 % ) , and no grade 4 vintafolide drug - related adverse events ( AEs ) were reported ( Morris et al . , 2014 ) . In the open - label Phase 2 EC - FV - 03 vintafolide study in patients with progressive lung adenocarcinoma , a superior clinical ben - eﬁt response of 50 % was noted in patients with FR + + tumors ( n = 14 ) versus 14 . 3 % in patients with FR + tumors ( n = 14 ) ( P = 0 . 10 ) ( Edelman et al . , 2012a ) . Median OS was 47 . 2 weeks in patients with FR + + tumors and 14 . 9 weeks in patients with FR + tumors ( hazard ratio [ HR ] = 0 . 54 ; P = 0 . 101 ) ( Edelman et al . , 2012a ; Leamon et al . , 2012 ) . However , the primary objective of clinical beneﬁt response was not met in the overall study population ( Edelman et al . , 2012a ) . No grade 4 treatment - related AEs were reported ; grade 3 fatigue was observed in 4 . 7 % of patients , anorexia in 2 . 3 % , and peripheral neuropathy in 2 . 3 % ( Edelman et al . , 2012a ) . The open - label , randomized Phase 2 PRECEDENT ( EC - FV - 04 ) study investigated pegylated liposomal doxorubicin ( PLD ) with or without vintafolide in patients with platinum - resistant ovarian cancer ( Naumann et al . , 2013 ) . Median PFS in the overall study population was higher in the vintafolide - plus - PLD arm than in the PLD - alone arm : 5 . 0 versus 2 . 7 months , respectively ( HR = 0 . 63 ; 95 % conﬁdence interval [ CI ] , 0 . 41 – 0 . 96 ; P = 0 . 031 ) . As might be expected , the greatest beneﬁt was observed in patients with FR + + ( 100 % of lesions were FR positive ) tumors ( HR = 0 . 381 ; P = 0 . 013 ) , for whom the median PFS was 5 . 5 months in the vintafolide - plus - PLD arm compared with 1 . 5 months in the PLD - alone arm . In patients with only FR + tumors ( 10 % – 90 % of lesions were FR positive ) , as FR positivity decreased , PFS improvement in the combination arm over the PLD - alone arm was reduced to an HR of 0 . 873 . Finally , patients with FR − tumors ( disease that did not express FR ) expe - rienced no PFS beneﬁt ( HR = 1 . 806 ) ( Naumann et al . , 2013 ) . Thus , the ability of 99m Tc - etarfolatide to predict the antitumor response of vintafolide in patients with FR - positive tumors was validated in the clinical setting . Overall , the drug combination was well tol - erated , with no cumulative treatment - emergent adverse events ( TEAEs ) other than hand – foot syndrome . Most TEAEs were grade 1 or 2 . A nominal statistically signiﬁcant difference in the inci - dence of leukopenia was observed between treatment arms , but the difference was not clinically signiﬁcant , as no increase in febrile neutropenia or infection was noted ( Naumann et al . , 2013 ) . Vintafolide is being further investigated in multiple ongo - ing studies in which cancer patients with FR - positive tumors are being selected for treatment . In the Phase 2b TARGET study ( NCT01577654 ) , vintafolide is being evaluated as second - line treatment for NSCLC compared with vintafolide plus docetaxel or docetaxel alone . In the Phase 3 PROCEED study ( EC - FV - 06 ) ( NCT01170650 ) , vintafolide is being investigated in combination with PLD versus PLD plus placebo in patients with FR - positive , platinum - resistant ovarian cancer . At a pre - speciﬁed interim futility analysis , the Data Safety Monitoring Board ( DSMB ) rec - ommended that the study be stopped because the treatment combination did not meet the prespeciﬁed criteria for PFS to allow continuation of the study . The DSMB did not identify any safety concerns . In the Phase 1 study ( NCT01688791 ) , the safety and toler - ability of vintafolide in combination with carboplatin and paclitaxel Please cite this article in press as : Assaraf , Y . G . , et al . , The folate receptor as a rational therapeutic target for personalized cancer treatment . Drug Resist . Updat . ( 2014 ) , http : / / dx . doi . org / 10 . 1016 / j . drup . 2014 . 10 . 002 ARTICLE IN PRESS G Model YDRUP - 538 ; No . of Pages 7 6 Y . G . Assaraf et al . / Drug Resistance Updates xxx ( 2014 ) xxx – xxx are being evaluated in patients with endometrial cancer . In a Phase 2a study ( NCT01953536 ) , vintafolide and vintafolide plus paclitaxel will be evaluated versus paclitaxel alone in patients with triple - negative breast cancer who have 100 % FR + tumors . 4 . 3 . IMGN853 IMGN853 is an FR (cid:2) - targeting antibody – drug conjugate that has three components : an anti - FR (cid:2) monoclonal antibody that targets FR (cid:2) - positive cancer cells , a disulﬁde - based linker , and DM4 , a cyto - toxic maytansinoid which acts as a microtubule polymerization tubulin inhibitor ( Kurkjian et al . , 2013 ; Ab et al . , 2011 ) . This agent is being investigated in an ongoing Phase 1 study in patients with endometrial cancer and epithelial ovarian cancer ( NCT01609556 ) ; preliminary results show that IMGN83 is well tolerated ( Kurkjian et al . , 2013 ) . 5 . Conclusions The FR plays a pivotal role in cancer development , progres - sion , and metastasis and is emerging as an effective therapeutic target for personalized medicine . Moreover , evidence from clini - cal studies with different solid tumors of secretory epithelial origin suggests that the FR may also be a negative prognostic marker asso - ciated with chemoresistance in certain malignancies . The available diagnostic tools for detecting FR levels require a tumor biopsy , high - lighting the need for sensitive , reliable , robust , and noninvasive diagnostics . Etarfolatide is being developed as a companion imag - ing agent to the FR - targeted therapeutic , vintafolide . Its potential use in predicting response to vintafolide is being explored in mul - tiple clinical trials . Additional agents under clinical investigation include farletuzumab and IMGN853 . Targeted therapy that exploits the FR represents a promising opportunity for a more personalized medicine approach for the treatment of malignant and nonma - lignant diseases . The recent availability of the crystal structures of FR (cid:2) and FR (cid:3) in complex with folates and antifolates forms a realistic basis for the rational design and implementation of novel FR - targeted drugs for the treatment of cancer and inﬂammatory diseases . Competing interests Yehuda G . Assaraf has no conﬂict of interest to report . Christo - pher P . Leamon and Joseph A . Reddy are employees of Endocyte , Inc . Acknowledgements Medical writing assistance was provided by Mark English , Ph . D . , and Matt Grzywacz , Ph . D . , of ApotheCom ( Yardley , PA ) . This assis - tance was funded by Merck & Co . , Inc . , Whitehouse Station , NJ . References Armstrong , D . K . , White , A . J . , Weil , S . C . , Phillips , M . , Coleman , R . L . , 2013 . Farletuzumab ( a monoclonal antibody against folate receptor alpha ) in relapsed platinum - sensitive ovarian cancer . Gynecol . Oncol . 129 , 452 – 458 . Awada , A . , Aftimos , P . G . , 2013 . Targeted therapies of solid cancers : new options , new challenges . Curr . Opin . Oncol . 25 , 296 – 304 . Banerjee , S . , Kaye , S . B . , 2013 . New strategies in the treatment of ovarian cancer : current clinical perspectives and future potential . Clin . Cancer Res . 19 , 961 – 968 . Baumann , K . H . , Wagner , U . , du Bois , A . , 2012 . The changing landscape of therapeutic strategies for recurrent ovarian cancer . Future Oncol . 8 , 1135 – 1147 . Bremer , R . E . , Scoggin , T . S . , Somers , E . B . , O’Shannessy , D . J . , Tacha , D . E . , 2013 . Interob - server agreement and assay reproducibility of folate receptor alpha expression in lung adenocarcinoma : a prognostic marker and potential therapeutic target . Arch . Pathol . Lab . Med . 137 , 1747 – 1752 . Bueno , R . , Appasani , K . , Mercer , H . , Lester , S . , Sugarbaker , D . , 2001 . The alpha folate receptor is highly activated in malignant pleural mesothelioma . J . Thorac . Car - diovasc . Surg . 121 , 225 – 233 . Burrell , R . A . , McGranahan , N . , Bartek , J . , Swanton , C . , 2013 . The causes and conse - quences of genetic heterogeneity in cancer evolution . Nature 501 , 338 – 345 . Chen , Y . L . , Chang , M . C . , Huang , C . Y . , Chiang , Y . C . , Lin , H . W . , Chen , C . A . , Hsieh , C . Y . , Cheng , W . F . , 2012 . Serous ovarian carcinoma patients with high alpha - folate receptor had reducing survival and cytotoxic chemo - response . Mol . Oncol . 6 , 360 – 369 . Christoph , D . C . , Asuncion , B . R . , Hassan , B . , Tran , C . , Maltzman , J . D . , O’Shannessy , D . J . , Wynes , M . W . , Gauler , T . C . , Wohlschlaeger , J . , Hoiczyk , M . , Schuler , M . , Eberhardt , W . E . , Hirsch , F . R . , 2013 . Signiﬁcance of folate receptor alpha and thymidylate synthase protein expression in patients with non - small - cell lung cancer treated with pemetrexed . J . Thorac . Oncol . 8 , 19 – 30 . Crane , L . M . , Arts , H . J . , van Oosten , M . , Low , P . S . , van der Zee , A . G . , van Dam , G . M . , Bart , J . , 2012 . The effect of chemotherapy on expression of folate receptor - alpha in ovarian cancer . Cell Oncol . 35 , 9 – 18 . Della - Longa , S . , Arcovito , A . , 2013 . Structural and functional insights on folate receptor alpha ( FRalpha ) by homology modeling , ligand docking and molecular dynamics . J . Mol . Graph . Model . 44 , 197 – 207 . Despierre , E . , Lambrechts , S . , Leunen , K . , Berteloot , P . , Neven , P . , Amant , F . , O’Shannessy , D . J . , Somers , E . B . , Vergote , I . , 2013 . Folate receptor alpha ( FRA ) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy . Gynecol . Oncol . 130 , 192 – 199 . Dosio , F . , Milla , P . , Cattel , L . , 2010 . EC - 145 , a folate - targeted Vinca alkaloid conjugate for the potential treatment of folate receptor - expressing cancers . Curr . Opin . Investig . Drugs 11 , 1424 – 1433 . Drebin , J . A . , Link , V . C . , Weinberg , R . A . , Greene , M . I . , 1986 . Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene - encoded tumor antigen . Proc . Natl . Acad . Sci . U . S . A . 83 , 9129 – 9133 . Edelman , M . J . , Harb , W . A . , Pal , S . E . , Boccia , R . V . , Kraut , M . J . , Bonomi , P . , Conley , B . A . , Rogers , J . S . , Messmann , R . A . , Garon , E . B . , 2012a . Multicenter trial of EC145 in advanced , folate - receptor positive adenocarcinoma of the lung . J . Thorac . Oncol . 7 , 1618 – 1621 . Edelman , M . J . , Bonomi , P . , Harb , W . , Pal , S . , Boccia , R . , Kraut , M . , Rogers , J . , Mor - genstern , D . , Conley , B . , Garon , E . , 2012b . Co - development of a folate receptor targeted drug conjugate ( EC145 ) and a folate receptor targeted imaging agent ( EC20 ) in the treatment of advanced adenocarcinoma NSCLC . J . Thorac . Oncol . 7 ( 6 ( Suppl . 1 ) ) , S63 . Elnakat , H . , Ratnam , M . , 2006 . Role of folate receptor genes in reproduction and related cancers . Front . Biosci . 11 , 506 – 519 . Fisher , R . E . , Siegel , B . A . , Edell , S . L . , Oyesiku , N . M . , Morgenstern , D . E . , Messmann , R . A . , Amato , R . J . , 2008 . Exploratory study of 99mTc - EC20 imaging for iden - tifying patients with folate receptor - positive solid tumors . J . Nucl . Med . 49 , 899 – 906 . Franklin , W . A . , Waintrub , M . , Edwards , D . , Christensen , K . , Prendegrast , P . , Woods , J . , Bunn , P . A . , Kolhouse , J . F . , 1994 . New anti - lung - cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma . Int . J . Cancer 57 ( Suppl . 8 ) , 89 – 95 . Garin - Chesa , P . , Campbell , I . , Saigo , P . E . , Lewis Jr . , J . L . , Old , L . J . , Rettig , W . J . , 1993 . Trophoblast and ovarian cancer antigen LK26 . Sensitivity and speciﬁcity in immunopathology and molecular identiﬁcation as a folate - binding protein . Am . J . Pathol . 142 , 557 – 567 . Gerlinger , M . , Horswell , S . , Larkin , J . , Rowan , A . J . , Salm , M . P . , Varela , I . , Fisher , R . , McGranahan , N . , Matthews , N . , Santos , C . R . , Martinez , P . , Phillimore , B . , Begum , S . , Rabinowitz , A . , Spencer - Dene , B . , Gulati , S . , Bates , P . A . , Stamp , G . , Pickering , L . , Gore , M . , Nicol , D . L . , Hazell , S . , Futreal , P . A . , Stewart , A . , Swanton , C . , 2014 . Genomic architecture and evolution of clear cell renal cell carcinomas deﬁned by multiregion sequencing . Nat . Genet . 46 , 225 – 233 . Gonen , N . , Assaraf , Y . G . , 2012 . Antifolates in cancer therapy : structure , activity and mechanisms of drug resistance . Drug Resist . Updat . 15 , 183 – 210 . Gonzalez de Castro , D . , Clarke , P . A . , Al - Lazikani , B . , Workman , P . , 2013 . Personal - ized cancer medicine : molecular diagnostics , predictive biomarkers , and drug resistance . Clin . Pharmacol . Ther . 93 , 252 – 259 . Hartmann , L . C . , Keeney , G . L . , Lingle , W . L . , Christianson , T . J . , Varghese , B . , Hillman , D . , Oberg , A . L . , Low , P . S . , 2007 . Folate receptor overexpression is associated with poor outcome in breast cancer . Int . J . Cancer 121 , 938 – 942 . Ifergan , I . , Assaraf , Y . G . , 2008 . Molecular mechanisms of adaptation to folate deﬁ - ciency . Vitam . Horm . 79 , 99 – 143 . Jager , N . A . , Teteloshvili , N . , Zeebregts , C . J . , Westra , J . , Bijl , M . , 2012 . Macrophage folate receptor - beta ( FR - beta ) expression in auto - immune inﬂammatory rheumatic diseases : a forthcoming marker for cardiovascular risk ? Autoimmun . Rev . 11 , 621 – 626 . Jonsson , B . , Bergh , J . , 2012 . Hurdles in anticancer drug development from a regula - tory perspective . Nat . Rev . Clin . Oncol . 9 , 236 – 243 . Kalli , K . R . , Oberg , A . L . , Keeney , G . L . , Christianson , T . J . , Low , P . S . , Knutson , K . L . , Hart - mann , L . C . , 2008 . Folate receptor alpha as a tumor target in epithelial ovarian cancer . Gynecol . Oncol . 108 , 619 – 626 . Kurkjian , C . , LoRusso , P . , Sankhala , K . K . , Birrer , M . J . , Kirby , M . , Ladd , S . , Hawes , S . , Running , K . L . , O’Leary , J . J . , Moore , K . N . , 2013 . A phase I , ﬁrst - in - human study to evaluate the safety , pharmacokinetics ( PK ) , and pharmacodynamics ( PD ) of IMGN853 in patients ( Pts ) with epithelial ovarian cancer ( EOC ) and other FOLR1 - positive solid tumors . J . Clin . Oncol . 31 ( 15 Suppl . ) , 2573 . Konner , J . A . , Bell - McGuinn , K . M . , Sabbatini , P . , Hensley , M . L . , Tew , W . P . , Pandit - Taskar , N . , Vander , E . N . , Phillips , M . D . , Schweizer , C . , Weil , S . C . , Larson , S . M . , Old , L . J . , 2010 . Farletuzumab , a humanized monoclonal antibody against folate Please cite this article in press as : Assaraf , Y . G . , et al . , The folate receptor as a rational therapeutic target for personalized cancer treatment . Drug Resist . Updat . ( 2014 ) , http : / / dx . doi . org / 10 . 1016 / j . drup . 2014 . 10 . 002 ARTICLE IN PRESS G Model YDRUP - 538 ; No . of Pages 7 Y . G . Assaraf et al . / Drug Resistance Updates xxx ( 2014 ) xxx – xxx 7 receptor alpha , in epithelial ovarian cancer : a phase I study . Clin . Cancer Res . 16 , 5288 – 5295 . Lasry , I . , Berman , B . , Straussberg , R . , Sofer , Y . , Bessler , H . , Sharkia , M . , Glaser , F . , Jansen , G . , Drori , S . , Assaraf , Y . G . , 2008 . A novel loss - of - function mutation in the proton - coupled folate transporter from a patient with hereditary folate malabsorption reveals that Arg 113 is crucial for function . Blood 112 , 2055 – 2061 . Leamon , C . P . , Parker , M . A . , Vlahov , I . R . , Xu , L . C . , Reddy , J . A . , Vetzel , M . , Douglas , N . , 2002 . Synthesis and biological evaluation of EC20 : a new folate - derived ( 99m ) Tc - based radiopharmaceutical . Bioconjug . Chem . 13 , 1200 – 1210 . Leamon , C . P . , Reddy , J . A . , Bloomﬁeld , A . , Dorton , R . , Nelson , M . , Klein , P . J . , Vlahov , I . R . , Vetzel , M . , 2012 . Predicting response to EC145 therapy using the folate receptor - speciﬁc radiodiagnostic imaging agent , 99m Tc - EC20 . Cancer Res . 72 ( 8 ( Suppl . 1 ) ) , 3622 . Li , P . Y . , Del , V . S . , Fonti , R . , Carriero , M . V . , Potena , M . I . , Botti , G . , Miotti , S . , Lastoria , S . , Menard , S . , Colnaghi , M . I . , Salvatore , M . , 1996 . Local concentration of folate bind - ing protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography . J . Nucl . Med . 37 , 665 – 672 . Livney , Y . D . , Assaraf , Y . G . , 2013 . Rationally designed nanovehicles to overcome can - cer chemoresistance . Adv . Drug Deliv . Rev . 65 , 1716 – 1730 . Matherly , L . H . , Wilson , M . R . , Hou , Z . , 2014 . The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1 : biology and role in antifolate chemotherapy of cancer . Drug Metab . Dispos . 42 , 632 – 649 . Mendelsohn , J . , 2013 . Personalizing oncology : perspectives and prospects . J . Clin . Oncol . 31 , 1904 – 1911 . Morris , R . , Joyrich , R . N . , Naumann , R . W . , Shah , N . P . , Mauer , A . H . , Strauss , H . W . , Uszler , J . M . , Symanowski , J . T . , Ellis , P . R . , Harb , W . A . , 2014 . Phase II study of treatment of advanced ovarian cancer with folate - receptor - targeted therapeutic ( vintafolide ) and companion SPECT - based imaging agent ( 99mTc - etarfolatide ) . Ann . Oncol . 25 , 852 – 858 . Muller , C . , 2012 . Folate based radiopharmaceuticals for imaging and therapy of cancer and inﬂammation . Curr . Pharm . Des . 18 , 1058 – 1083 . Naumann , R . W . , Coleman , R . L . , Burger , R . A . , Sausville , E . A . , Kutarska , E . , Ghamande , S . A . , Gabrail , N . Y . , DePasquale , S . E . , Nowara , E . , Gilbert , L . , Gersh , R . H . , Tener - iello , M . G . , Harb , W . A . , Konstantinopoulos , P . A . , Penson , R . T . , Symanowski , J . T . , Lovejoy , C . D . , Leamon , C . P . , Morgenstern , D . E . , Messmann , R . A . , 2013 . PRECE - DENT : a randomized phase II trial comparing vintafolide ( EC145 ) and pegylated liposomal doxorubicin ( PLD ) in combination versus PLD alone in patients with platinum - resistant ovarian cancer . J . Clin . Oncol . 31 , 4400 – 4406 . Nunez , M . I . , Behrens , C . , Woods , D . M . , Lin , H . , Suraokar , M . , Kadara , H . , Hofstetter , W . , Kalhor , N . , Lee , J . J . , Franklin , W . , Stewart , D . J . , Wistuba , I . I . , 2012 . High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [ corrected ] mutation . J . Thorac . Oncol . 7 , 833 – 840 . O’Shannessy , D . J . , Somers , E . B . , Albone , E . , Cheng , X . , Park , Y . C . , Tomkowicz , B . E . , Hamuro , Y . , Kohl , T . O . , Forsyth , T . M . , Smale , R . , Fu , Y . S . , Nicolaides , N . C . , 2011 . Characterization of the human folate receptor alpha via novel antibody - based probes . Oncotarget 2 , 1227 – 1243 . O’Shannessy , D . J . , Somers , E . B . , Palmer , L . M . , Thiel , R . P . , Oberoi , P . , Heath , R . , Mar - cucci , L . , 2013 . Serum folate receptor alpha , mesothelin and megakaryocyte potentiating factor in ovarian cancer : association to disease stage and grade and comparison to CA125 and HE4 . J . Ovarian Res . 6 , 29 . Ab , O . , Bartle , L . M . , Rui , L . , Coccia , J . , Johnson , H . A . , Whiteman , K . R . , Kellogg , B . , Clancy , L . , Sun , X . , Goldmacher , V . S . , 2011 . IMGN853 , an anti - folate receptor I antibody - maytansinoid conjugate for targeted cancer therapy . Cancer Res . 71 ( 8 ( Suppl . 1 ) ) , 4576 . Parker , N . , Turk , M . J . , Westrick , E . , Lewis , J . D . , Low , P . S . , Leamon , C . P . , 2005 . Folate receptor expression in carcinomas and normal tissues determined by a quanti - tative radioligand binding assay . Anal . Biochem . 338 , 284 – 293 . Pribble , P . , Edelman , M . J . , 2012 . EC145 : a novel targeted agent for adenocarcinoma of the lung . Expert Opin . Investig . Drugs 21 , 755 – 761 . Qiu , A . , Jansen , M . , Sakaris , A . , Min , S . H . , Chattopadhyay , S . , Tsai , E . , Sandoval , C . , Zhao , R . , Akabas , M . H . , Goldman , I . D . , 2006 . Identiﬁcation of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption . Cell 127 , 917 – 928 . Reddy , J . A . , Dorton , R . , Westrick , E . , Dawson , A . , Smith , T . , Xu , L . C . , Vetzel , M . , Kleindl , P . , Vlahov , I . R . , Leamon , C . P . , 2007 . Preclinical evaluation of EC145 , a folate – vinca alkaloid conjugate . Cancer Res . 67 , 4434 – 4442 . Reddy , J . A . , Xu , L . C . , Parker , N . , Vetzel , M . , Leamon , C . P . , 2004 . Preclinical evaluation of ( 99m ) Tc - EC20 for imaging folate receptor - positive tumors . J . Nucl . Med . 45 , 857 – 866 . Ross , J . F . , Chaudhuri , P . K . , Ratnam , M . , 1994 . Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines . Physiologic and clinical implications . Cancer 73 , 2432 – 2443 . Salazar , M . D . , Ratnam , M . , 2007 . The folate receptor : what does it promise in tissue - targeted therapeutics ? Cancer Metastasis Rev . 26 , 141 – 152 . Sega , E . I . , Low , P . S . , 2008 . Tumor detection using folate receptor - targeted imaging agents . Cancer Metastasis Rev . 27 , 655 – 664 . Shia , J . , Klimstra , D . S . , Nitzkorski , J . R . , Low , P . S . , Gonen , M . , Landmann , R . , Weiser , M . R . , Franklin , W . A . , Prendergast , F . G . , Murphy , L . , Tang , L . H . , Temple , L . , Guillem , J . G . , Wong , W . D . , Paty , P . B . , 2008 . Immunohistochemical expression of folate receptor alpha in colorectal carcinoma : patterns and biological signiﬁcance . Hum . Pathol . 39 , 498 – 505 . Sia , D . , Alsinet , C . , Newell , P . , Villanueva , A . , 2013 . VEGF signaling in cancer treatment . Curr . Pharm . Des . 20 , 2834 – 2842 . Siu , M . K . , Kong , D . S . , Chan , H . Y . , Wong , E . S . , Ip , P . P . , Jiang , L . , Ngan , H . Y . , Le , X . F . , Cheung , A . N . , 2012 . Paradoxical impact of two folate receptors , FRalpha and RFC , in ovarian cancer : effect on cell proliferation , invasion and clinical outcome . PLOS ONE 7 , e47201 . Straussman , R . , Morikawa , T . , Shee , K . , Barzily - Rokni , M . , Qian , Z . R . , Du , J . , Davis , A . , Mongare , M . M . , Gould , J . , Frederick , D . T . , Cooper , Z . A . , Chapman , P . B . , Solit , D . B . , Ribas , A . , Lo , R . S . , Flaherty , K . T . , Ogino , S . , Wargo , J . A . , Golub , T . R . , 2012 . Tumour micro - environment elicits innate resistance to RAF inhibitors through HGF secretion . Nature 487 , 500 – 504 . Teng , L . , Xie , J . , Teng , L . , Lee , R . J . , 2012 . Clinical translation of folate receptor - targeted therapeutics . Expert Opin . Drug Deliv . 9 , 901 – 908 . Thomas , A . , Maltzman , J . , Hassan , R . , 2013 . Farletuzumab in lung cancer . Lung Cancer 80 , 15 – 18 . Toffoli , G . , Cernigoi , C . , Russo , A . , Gallo , A . , Bagnoli , M . , Boiocchi , M . , 1997 . Over - expression of folate binding protein in ovarian cancers . Int . J . Cancer 74 , 193 – 198 . Toffoli , G . , Russo , A . , Gallo , A . , Cernigoi , C . , Miotti , S . , Sorio , R . , Tumolo , S . , Boiocchi , M . , 1998 . Expression of folate binding protein as a prognostic factor for response to platinum - containing chemotherapy and survival in human ovarian cancer . Int . J . Cancer 79 , 121 – 126 . Vanneman , M . , Dranoff , G . , 2012 . Combining immunotherapy and targeted therapies in cancer treatment . Nat . Rev . Cancer 12 , 237 – 251 . Veggian , R . , Fasolato , S . , Menard , S . , Minucci , D . , Pizzetti , P . , Regazzoni , M . , Tagliabue , E . , Colnaghi , M . I . , 1989 . Immunohistochemical reactivity of a monoclonal anti - body prepared against human ovarian carcinoma on normal and pathological female genital tissues . Tumori 75 , 510 – 513 . Walters , C . L . , Arend , R . C . , Armstrong , D . K . , Naumann , R . W . , Alvarez , R . D . , 2013 . Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer . Gynecol . Oncol . 131 , 493 – 498 . Weitman , S . D . , Lark , R . H . , Coney , L . R . , Fort , D . W . , Frasca , V . , Zurawski Jr . , V . R . , Kamen , B . A . , 1992 . Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues . Cancer Res . 52 , 3396 – 3401 . Wibowo , A . S . , Singh , M . , Reeder , K . M . , Carter , J . J . , Kovach , A . R . , Meng , W . , Ratnam , M . , Zhang , F . , Dann 3rd , C . E . , 2013 . Structures of human folate receptors reveal biological trafﬁcking states and diversity in folate and antifolate recognition . Proc . Natl . Acad . Sci . U . S . A . 110 , 15180 – 15188 . Wolff , A . C . , Hammond , M . E . , Schwartz , J . N . , Hagerty , K . L . , Allred , D . C . , Cote , R . J . , Dowsett , M . , Fitzgibbons , P . L . , Hanna , W . M . , Langer , A . , McShane , L . M . , Paik , S . , Pegram , M . D . , Perez , E . A . , Press , M . F . , Rhodes , A . , Sturgeon , C . , Taube , S . E . , Tubbs , R . , Vance , G . H . , van de Vijver , M . , Wheeler , T . M . , Hayes , D . F . , 2007 . American Society of Clinical Oncology / College of American Pathologists guideline recom - mendations for human epidermal growth factor receptor 2 testing in breast cancer . Arch . Pathol . Lab . Med . 131 , 18 – 43 . Zhao , R . , Goldman , I . D . , 2013 . The proton - coupled folate transporter : physiological and pharmacological roles . Curr . Opin . Pharmacol . 13 , 875 – 880 . Zhao , R . , Min , S . H . , Qiu , A . , Sakaris , A . , Goldberg , G . L . , Sandoval , C . , Malatack , J . J . , Rosenblatt , D . S . , Goldman , I . D . , 2007 . The spectrum of mutations in the PCFT gene , coding for an intestinal folate transporter , that are the basis for hereditary folate malabsorption . Blood 110 , 1147 – 1152 .